Cancer Pain | Pharmacor | G7 | 2015

Improving survival among those with advanced cancer along with a high rate of cancer-related pain in this patient population will lead to steady growth in the prevalence of cancer pain in the seven major markets under study throughout the ten-year forecast period. However, treatment of cancer-related pain will not change dramatically over the next decade because of a dearth of new therapies. Indeed, strong opioid analgesics will continue to be the mainstay of treatment for severe types of cancer pain, accounting for more than 90% of major-market drug sales for cancer pain in 2014 and 2024. Overall, we expect only modest growth in the $2 billion cancer pain market throughout our ten-year forecast period.

Login to access report